Stockreport

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024 [Seeking Alpha]

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF The company is facing patent challenges from generics, with the potential for a generic version of cabozantinib to launch in 2026. Exelixis is working on developing a [Read more]